NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) has reported encouraging clinical and regulatory developments for its lead candidate NEO100 and its second program NEO212, according to an update from Stonegate Capital Partners. The Phase 2a trial of NEO100 in recurrent brain cancer met its primary endpoint, demonstrating a six-month progression-free survival (PFS-6) of 48.9% using RANO 2.0 criteria via Kaplan-Meier estimation, compared against a pre-specified 20% benchmark (p=0.0047). The median overall survival (OS) reached 26.09 months, and no major toxicities were reported.
The survival data are particularly noteworthy, as current salvage therapy for recurrent brain cancer typically offers only 6–9 months of benefit. This readout positions NEO100 as a potential registrational candidate, with the company intending to request a Type B FDA meeting to discuss the trial design and approval pathway. The positive tolerability profile supports its use as a chronic, patient-friendly treatment, potentially expanding its therapeutic application.
Beyond NEO100, NEO212 has gained regulatory momentum, receiving Phase 2 CMC clearance and FDA feedback suggesting a potential accelerated approval pathway. This broadens the investment case, as NEO100 is also being explored in meningioma and pediatric brain tumors, while NEO212 offers a differentiated second clinical program. The platform's depth increases long-term optionality, though funding remains a key consideration as development activities expand.
Financial results were secondary to clinical progress, with R&D expenses increasing to $2.6 million from $0.7 million year-over-year, reflecting heightened development activity. The company's focus now shifts to FDA alignment, which is the near-term catalyst that could define the registrational path for NEO100.
